Canna~Fangled Abstracts

The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.

By April 18, 2012 No Comments
2012 Apr;1(2):64-75. doi: 10.1016/j.msard.2011.11.001. Epub 2012 Jan 18.


PM 1aCannabis-based medicines have recently been approved for the treatment of pain and spasticity in multiple sclerosis (MS). This supports the original perceptions of people with MS, who were using illegal street cannabis for symptom control and pre-clinical testing in animal models of MS. This activity is supported both by the biology of the disease and the biology of the cannabis plant and the endocannabinoid system. MS results from disease that impairs neurotransmission and this is controlled by cannabinoid receptors and endogenous cannabinoid ligands. This can limit spasticity and may also influence the processes that drive the accumulation of progressive disability.
Copyright © 2011 Elsevier B.V. All rights reserved.


Cannabis; Endocannabinnoid; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Neuroprotection; Spasticity






Publication Types

Publication Types

 twin memes II
en English